Charting a roadmap for heart failure biomarker studies

JACC: Heart Failure

Volumn 2, Issue 5, 2014, Pages 477-488

  Ahmad, Tariq ^a,b   Fiuzat, Mona ^a,b   Pencina, Michael J ^a   Geller, Nancy L ^c   Zannad, Faiez ^d   Cleland, John G F ^e   Snider, James V ^f   Blankenberg, Stephan ^g   Adams, Kirkwood F ^h   Redberg, Rita F ⁱ   Kim, Jae B ^j   Mascette, Alice ^c   Mentz, Robert J ^a   O'Connor, Christopher M ^a,b   Felker, G Michael ^a,b   Januzzi, James L ^a,k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIVERSITY OF HULL   (United Kingdom)

^f Critical Diagnostics   (United States)

^g JOHANNES GUTENBERG UNIVERSITY   (Germany)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j AMGEN INC   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Biomarkers; Heart failure; Studies

Indexed keywords

ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; GALECTIN 3; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; VALSARTAN;

CLINICAL DECISION MAKING; DIAGNOSTIC VALUE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STABLE ANGINA PECTORIS; SYSTOLIC HEART FAILURE; THROMBOCYTE FUNCTION ANALYZER; BLOOD; COOPERATION; METHODOLOGY;

BIOMARKERS; COOPERATIVE BEHAVIOR; HEART FAILURE; HUMANS; PROGNOSIS; RESEARCH DESIGN;

EID: 84908105700     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.02.005     Document Type: Review

References (51)

1. Calaprice A. The Ultimate Quotable Einstein 2010, Princeton University Press, Princeton, NJ.
2. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008, 117:2544-2565.
3. Lee D.S., Tu J.V., Juurlink D.N., et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005, 294:1240-1247.
4. Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012, 9:347-359.
5. van Kimmenade R.R., Januzzi J.L. Emerging biomarkers in heart failure. Clin Chem 2012, 58:127-138.
6. Braunwald E. Biomarkers in heart failure. NEngl J Med 2008, 358:2148-2159.
7. Maisel A.S., Daniels L.B. Breathing Not Properly 10 years later: what we have learned and what westill need to learn. JAm Coll Cardiol 2012, 60:277-282.
8. Januzzi J.L., Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 2013, 127:500-507.
9. Desai A.S. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation 2013, 127:509-516.
10. Savarese G., Trimarco B., Dellegrottaglie S., et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PloS One 2013, 8:e58287.
11. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416.
12. Maisel A.S. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEngl J Med 2002, 347:161-167.
13. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 62:e147-e239.
14. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005, 95:948-954.
15. Allen L.A. Use of multiple biomarkers in heart failure. Curr Cardiol Rep 2010, 12:230-236.
16. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
17. Levy W.C., Mozaffarian D., Linker D.T., et al. TheSeattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006, 113:1424-1433.
18. Morrow D.A., Cook N.R. Determining decision limits for new biomarkers: clinical and statistical considerations. Clin Chem 2011, 57:1-3.
19. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003, 49:1-6.
20. Cook N.R. Assessing the incremental role of novel and emerging risk factors. Curr Cardiovasc Risk Rep 2010, 4:112-119.
21. Cook N.R., Ridker P.M. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009, 150:795-802.
22. Steyerberg E.W., Pencina M.J. Reclassification calculations for persons with incomplete follow-up. Ann Intern Med 2010, 152:195-196.
23. Spevack D.M., Chandra R. Changes in cardiac geometry and function after gastric bypass surgery. JAm Coll Cardiol 2011, 58:1924.
24. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
25. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
26. Pencina M.J., D'Agostino R.B., Pencina K.M., Janssens A.C., Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012, 176:473-481.
27. Pencina M.J., D'Agostino R.B., Vasan R.S. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010, 48:1703-1711.
28. Fine J., Gray R. Aproportional hazards model for the subdistribution ofa competing risk. JAm Stat Assoc 1999, 94:496-509.
29. Van Calster B., Van Belle V., Vergouwe Y., Timmerman D., Van Huffel S., Steyerberg E.W. Extending the c-statistic to nominal polytomous outcomes: the polytomous discrimination index. Stat Med 2012, 31:2610-2626.
30. Seymour C.W., Cooke C.R., Wang Z., et al. Improving risk classification of critical illness with biomarkers: a simulation study. JCrit Care 2013, 28:541-548.
31. Vickers A.J., Elkin E.B. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006, 26:565-574.
32. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
33. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.
34. Freidlin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: design issues. JNatl Cancer Inst 2010, 102:152-160.
35. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. NEngl J Med 2007, 357:2248-2261.
36. Gullestad L., Ueland T., Kjekshus J., et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012, 33:2290-2296.
37. Wollert K.C. Tailored therapy for heart failure: the role of biomarkers. Eur Heart J 2012, 33:2246-2248.
38. Anand I.S., Rector T.S., Kuskowski M., Adourian A., Muntendam P., Cohn J.N. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15:511-518.
39. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
40. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
41. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
42. Weiner R.B., Baggish A.L., Chen-Tournoux A., et al. Improvement instructural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 2013, 15:342-351.
43. Bhardwaj A., Rehman S.U., Mohammed A.A., et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J 2012, 164:793-799.e1.
44. Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013, 310:66-74.
45. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003, 138:40-44.
46. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003, 138:W1-W12.
47. Ky B., French B., Levy W.C., et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
48. Wang T.J., Wollert K.C., Larson M.G., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012, 126:1596-1604.
49. Berriz G.F., King O.D., Bryant B., Sander C., Roth F.P. Characterizing gene sets with FuncAssociate. Bioinformatics 2003, 19:2502-2504.
50. Barabasi A.L., Gulbahce N., Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12:56-68.
51. Demaria A.N. Publication bias and journals as policemen. JAm Coll Cardiol 2004, 44:1707-1708.